Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, Texas --(BUSINESS WIRE)--Nov. 8, 2022-- Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized

IRVING, Texas --(BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms.

IRVING, Texas --(BUSINESS WIRE)--Oct. 31, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide third quarter financial results on Tuesday, November 8,

IRVING, Texas --(BUSINESS WIRE)--Oct. 10, 2022-- biote   Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time

Biote Method to be available in IMAC outpatient medical clinics IRVING, Texas --(BUSINESS WIRE)--Sep. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has

Company will resume trading under its existing symbols “BTMD” and “BTMDW” IRVING, Texas --(BUSINESS WIRE)--Aug. 25, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that The Nasdaq

IRVING, Texas --(BUSINESS WIRE)--Aug. 24, 2022-- biote Corp. (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as its Chief Financial Officer. Mr.

IRVING, Texas --(BUSINESS WIRE)--Aug. 15, 2022-- Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Second Quarter 2022 Financial Results,” issued on August 9, 2022 .

Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance * Revised Dial -in Information for the Conference Call* IRVING, Texas --(BUSINESS WIRE)--Aug. 9, 2022-- Biote , a high growth, differentiated medical practice-building business

IRVING, Texas --(BUSINESS WIRE)--Jul. 20, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022 , after market close on